Kornimate/medical-research-clean huggingface dataset:
validation of a personalised medicine tool for multiple myeloma that predicts treatment effectiveness in patients

Conditions: Multiple Myeloma

Summary: the consortium aims to commercialise the mmpredictor as a personalised medicine tool that predicts the most effective treatment strategy for individual multiple myeloma (mm) patients. mm is the second most common form of blood cancer contributing to 15% of all blood cancers and \~1,5% and 2% of all cancer deaths annually in the eu and us, respectively. patients show a large variability in treatment response and side effects due to tumour heterogeneity and the patient's intrinsic characteristics. therefore, not every treatment will be suitable for each patient, and treatment strategies are often based on trial-and-error. the availability of multiple (\>20) treatment options complicates treatment decision-making even more. with the current development of many more promising treatments, there is an urgent unmet clinical need for a diagnostic assay that supports personalised cancer treatment in order to improve patient health outcomes, prevent side effects and reduce healthcare costs. skylinedx has previously developed the mmprofiler, a microarray-based diagnostic test that can subtype mm patients and reliably predict mm patient survival (prognosis). in this project, the test's clinical value will be expanded to include the prediction of treatment effectiveness in individual patients based on gene expression profiling. an addendum for new intended use will be filed to the current in vitro diagnostic (ivd) registration, while renaming the test to mmpredictor. the project will also focus on positioning the test as a cost-effective ivd test for personalised medicine, that will increase health outcome and quality of life of patients and reduce healthcare costs. the consortium consists of a life science sme specialised in molecular diagnostics, clinical centres with world renowned kols, a leading health economic institute, and a european mm patient advocacy organisation combining all the required complementary expertise to successfully bring the mmpredictor to market.


Eligibility criteria:
inclusion criteria: * the bio-banked mm patient samples and clinical data will be obtained from previous european clinical trials that have been conducted over the past 5 years within the participating clinical centres and other clinical centers. the samples were not collected for the purposes of this project. the subjects from which the data was initially taken cannot be identified from the data/records. however, the patients from the above mentioned trial have explicitly consented for the use of their samples for other (future) clinical research purposes. exclusion criteria: -
use of cxcl9 as a biomarker of acthar efficacy

Conditions: Sarcoidosis

Summary: the objective is this study is to test whether use of acthar gel in the context of sarcoidosis will lead to improved symptoms and lung function and correlate with decreased levels of predictive blood biomarkers, like chemokine ligand 9 (cxcl9).

the investigators will test whether acthar gel's anti-inflammatory properties will modulate immune cells and lead to decreases in blood biomarkers and improvements in clinical parameters. specific aim 1 will examine the levels of the predictive biomarker, chemokine ligand 9 (cxcl9), and related transcripts, and determine whether they decrease in participants over time while taking acthar. specific aim 2 will test whether the biologic changes measured in blood correlate to clinical markers, including lung function and symptom scores. since the investigators have found that cxcl9 predicts clinical course, they hypothesize that cxcl9 transcript levels in the blood will decrease over time in pulmonary sarcoidosis participants whose clinical outcome measures improve with acthar.

Eligibility criteria:
inclusion criteria: * biopsy-proven diagnosis of sarcoidosis with demonstrated pulmonary involvement * refractoriness to or intolerance of immunosuppressive agents like prednisone or methotrexate exclusion criteria: * smoking * cancer * chronic infections (e.g. tuberculosis, viral, fungal, bacterial) * inflammatory conditions * coexisting lung disease * congestive heart failure * uncontrolled hypertension * recent surgery * active peptic ulcers * osteoporosis

Keywords: sarcoidosis acthar cxcl9 chemokine ligand 9
visual performance of multifocal intraocular lenses

Conditions: IOL; Cataract

Summary: to evaluate the clinical outcomes with an extended range of vision (erv) iol based on achromatic diffractive technology.

this was a prospective comparative study including 60 eyes undergoing cataract surgery with implantation of the erv tecnis symfony iol (abbott medical optics, inc.) (erv group: 60 eyes of 30 patients). visual, refractive, contrast sensitivity, defocus curve, ocular optical quality (optical quality analysis system; itrace), and visual function questionair（nei-vfq 25） outcomes were evaluated during a 3-month follow-up.

Eligibility criteria:
inclusion criteria: * visually significant cataract * age of 20 years or older * preoperative corneal astigmatism of 1.50 diopters (d) or lower. exclusion criteria: * previous ocular surgery * active ocular pathology * amblyopia * systemic or ocular medication that could affect vision * subclinical or clinical corneal ectatic disease * pupil abnormalities * intraoperative complication leading to capsular or zonular abnormalities

Keywords: multifocal iol ocular optical quality abberation
safety, tolerability, and immunogenicity study of acc-001 in japanese subjects with mild to moderate alzheimer's disease

Conditions: Alzheimer's Disease

Summary: the purpose of this study is to assess the safety, tolerability, and immunogenicity of acc-001, an investigational vaccine, in subjects with mild to moderate alzheimer's disease in japan.


Eligibility criteria:
inclusion criteria: * diagnosis of mild to moderate alzheimer's disease * mini-mental state examination (mmse) 16-26 exclusion criteria: * significant neurological disease other than alzheimer's disease * major psychiatric disorder * clinically significant systemic illness
amlodipine for myocardial iron in thalassemia

Conditions: Thalassemia

Summary: children with thalassemia may have high iron levels after receiving blood transfusions. these high iron levels can have damaging effects on the body, especially the heart. conventionally only chelation therapy was given for prevention of iron buildup in the heart. however, current research has shown that another drug, amlodipine, also helps to slow down the deposition of iron in the heart. this study is designed to see if patients receiving amlodipine along with their regular chelation therapy have a slower rate of iron buildup in the heart when compared with patients who are receiving chelation only.

null hypothesis there is no difference between the efficacy of chelation plus amlodipine therapy and chelation therapy alone in retarding the rate of myocardial iron deposition in thalassemia patients with iron overload and a constant transfusion need. alternate hypothesis chelation plus amlodipine therapy is more efficacious than chelation therapy alone in retarding the rate of myocardial iron deposition in thalassemia patients with iron overload and a constant transfusion need. the aim of the investigators study is to determine if amlodipine, an l-type specific calcium channel blocker, in addition to the standard aggressive chelation therapy, can retard the deposition of iron in the myocardium of thalassemia patients with significant myocardial iron load with or without cardiomyopathy.

Eligibility criteria:
inclusion criteria: * pediatric patients aged ≥ 6 and ≤ 20 years managed at akuh for at least 1 year * ≥ 10 blood transfusion in life time * transfusion need ≥ 180 ml/kg/year * serum ferritin ≥ 1000 ug/dl * patient deemed capable of receiving chelation therapy (by treating hematologist) either subcutaneous infusion of deferoxamine (desferal) (3-5 days a week) or oral deferasirox (daily) or defeperione (oral) or a combination of desferal and defeperione. * patients who have been on a stable chelation regimen ≥ 6 months * completed and signed informed consent/assent. exclusion criteria: * patients with known hypersensitivity to amlodipine. * patients with known sinoatrial nodal disease or aortic stenosis. * patients with known severe myocardial dysfunction, defined as a lv ejection fraction of ≤ 4 sd for age even without symptoms. * patients with known signs and symptoms of heart failure. * patients with a t2\* value of \< 4 ms on cardiac mri. * patients with systolic blood pressures ≤ 2 sd for age (systemic hypotension) at the time of enrolment. * patients with previously diagnosed significant congenital heart diseases or acquired heart diseases other than thalassemia (as defined earlier). * patients with known contraindications to mri (pacemakers, cerebral aneurysm metal clips, etc.) * patient with a known history of developing tetany after use of a calcium channel blocker * known pregnancy.

Keywords: thalassemia amlodipine chelation t2* mri myocardial iron
total parathyroidectomy with autotransplantation versus total parathyroidectomy alone for secondary hyperparathyroidism

Conditions: Secondary Hyperparathyroidism;Parathyroidectomy

Summary: total parathyroidectomy with autotransplantation (tptx+at) and total parathyr- oidectomy alone (tptx) are the common surgical procedures.the purpose of the study was to compare the long-term benefits of surgery between the two groups.

the trial was performed as a nonconfirmatory randomized controlled pilot trial with 200 patients on long-term dialysis with otherwise uncontrollable shpt to generate data on the rate of recurrent disease within a 5-year follow-up period after tptx or tptx+at. parathyroid hormone (pth) and calcium levels, recurrent or persistent hyperparathyroidism, parathyroid reoperations, morbidity, and mortality were evaluated during a 5-year follow-up.

Eligibility criteria:
inclusion criteria: severe renal secondary hyperparathyroidism exclusion criteria: patients with diabetes a history of chronic inflammatory disease a history of malignant tumor a history of kidney transplantation a history of neck surgery a history of alcohol abuse a history of drug abuse inability to cooperate with the participants refusal to participate in the study

Keywords: secondary hyperparathyroidism;parathyroidectomy;hemodialysis
the efficacy of elonide nasal corticosteroids in managing allergic rhinitis

Conditions: Allergic Rhinitis

Summary: the aim of this clinical study is to compare the efficacy of elonide nasal spray to nasonex nasal spray and placebo (non-active ingredient) in the management of allergic rhinitis. there are two hypotheses of this study: 1. elonide nasal spray is same efficacy to nasonex nasal spray. 2. elonide nasal spray is more efficient to placebo.

there are several objectives of the study: 1. to compare the efficacy of elonide to nasonex and placebo in treating allergic rhinitis via quality of life assessments and nasal airflow improvements. 2. to compare the efficacy of elonide to nasonex and placebo in treating allergic rhinitis via symptomatics improvement. 3. to assess the side effect of nasal spray given. patients who meet the criteria to join the study will be randomized in a double-blind manner (patients and investigators). patients will be given information about the study and consent form, patients will be randomized to 3 treatment group(elonide, nasonex, placebo). patients will be evaluated before and after treatment in one month time. patients will be advised to use the nasal spray twice daily.

Eligibility criteria:
inclusion criteria: * all adults patients 18 years and above * newly diagnosed mild, moderate to severe, intermittent and persistent allergic rhinitis * positive skin prick test or serum immunoglobulin e exclusion criteria: * patients who have been on allergic rhinitis treatment * below 18 years old * patients diagnosed with asthma or immunodeficiency diseases * pregnancy * other concomitant rhinology disease * smokers * severe deviated nasal septum
hemorrhoid radiofrequency

Conditions: Hemorrhoid Prolapse

Summary: triapedicular haemorroidectomy is currently the gold standard in haemorrhoidal pathology. minimally invasive surgical techniques now play an important role in the haemorrhoidal management algorithm, particularly for less advanced stages of the disease. among these techniques, radiofrequency is one of the most recent and is gradually gaining ground. it involves applying a radiofrequency current to the internal haemorrhoidal tissue in order to induce its involution. the literature has shown that this technique leads to symptomatic improvement in over 60% of cases and a high satisfaction rate, even though some patients still seem to have haemorrhoidal symptoms postoperatively. the aim of this study is to evaluate the efficacy of this technique in patients with haemorrhoidal pathology operated on at our centre, using "hard" criteria which are thought to be more rigorous ("cure" rather than "improvement").


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * presence of haemorrhoidal pathology * patient operated on between march 2017 and march 2023, using the radiofrequency technique * french-speaking patient exclusion criteria: * ano-perineal involvement in crohn's disease * perianal fistula * non-quiescent ibd * radiation-induced rectitis * psychiatric pathology. * under guardianship or curatorship * deprived of liberty * under court protection * patient objecting to the use of his/her data for this research

Keywords: radiofrequency
female upper genital tract in hiv-infected women

Conditions: HIV

Summary: the female upper genital tract is a unique compartment involved in hiv pathogenesis.

the persistent detection of hiv in the female genital tract in spite of art is unexplained, and it is possible the uterine endometrium serve as a reservoir. there are limited data regarding the interaction between hiv expression, antiretroviral therapy (art) and host immune system in the uterine endometrium.

Eligibility criteria:
inclusion criteria: * regularly menstruating women (between 21-42 days) * between ages 25-50 years * fully suppressed by antiretroviral therapy with plasma hiv rna \< 40 copies/ml within the last 6 months. exclusion criteria: * pregnant or planning pregnancy * unwilling to use 2 forms of contraception (condoms + hormonal) if they did not have previous bilateral tubal ligation procedure * intrauterine device in place * untreated cervical infection (n. gonnorhea, c. trachomatis) * taking immunosuppressive medications

Keywords: hiv female genital tract
the tick app: changing behaviors with educational messaging

Conditions: Tick Bites

Summary: the goal of this work is to evaluate the use of ecological momentary assessments as a tool to assess risk and risk factors for tick encounters and tick-borne diseases. this study will be conducted across the united states, with a focus the upper midwest and northeast and with a focus on wisconsin and will enroll up to 1000 people.

in the united states, several online and smart-phone apps are available to id a tick (tickid app, north carolina state university), submit a picture of a tick (tickspotters.org, an outreach tool within the larger tickencounter resource center by the university of rhode island) or submit a tick for testing (among other public health agencies, tickreport.com by the university of massachusetts amherst). although these tools are accessible throughout the u.s., they focus on the northeast. in addition, they do not assess human behavior and tick encounters nor do these tools evaluate prevention and education strategies. a recent study in the netherlands evaluated the use and effectiveness of a preventative and educational tick app ("tekenbeet"). this app was well-appreciated, well-used, and improved the user's intention to implement preventative measures. this also illustrates the move of information acquisition from in-hand leaflets to information provision through smartphones. in this study, data on human behavior regarding tick encounters and tick prevention measures will be obtained from a smartphone application using momentary assessments methodology to assess real time behavior and movement. ecological momentary assessments are a methodological tool for gathering quantitative behavioral data in real-time, or within the framework of a participant's daily routine. the daily logs feature provides researchers information about what the participant's activity, location, tick encounters, and prevention measures used. this study will analyze participants who complete 7 daily logs. their daily logs will be analyzed against the types of educational messaging presented to them within the tick app. during a portion of the year the opening screen will contain a prevention message and daily log reminder instead of the home screen. the screen will provide a tick check reminder, a link to the daily log and for half the users the screen will also include a reminder about another prevention behavior (for example bathing/showering). users will be randomly assigned to the two groups to assess if the additional prevention message increases prevention behavior (tick checks and showering/bathing) and the number of tick encounters.

Eligibility criteria:
inclusion criteria: * will to participate in 7 days worth of daily activity logs within the tick app. * be able and willing to provide informed consent exclusion criteria: * completes less than 7 days worth of daily logs or completes 7+ daily logs but not within 12 months.

Keywords: tick education behavior change tick bite prevention
mindfulness to reduce ambulatory hypertension in atrial fibrillation

Conditions: Atrial Fibrillation; Hypertension; Mindfulness; Cardiovascular Risk Reduction

Summary: the aim of this study is to evaluate the effectiveness of a 16 week mindfulness-based coaching program compared to a cardiovascular risk reduction education program. both groups will undergo 24-hour ambulatory blood pressure monitoring, along with assessments of psychological measures (see bellow) at study baseline, midpoint (8 weeks), and conclusion (16 weeks). in addition, both groups will also undergo 24-hour holter monitoring assessments at study beginning and conclusion to assess possible episodes of atrial tachyarrhythmia during the assessed interval.


Eligibility criteria:
inclusion criteria: * age 50-80 * diagnosed atrial fibrillation * night time (sleep time) systolic blood pressure≥120 or daytime (awake) systolic blood pressure ≥ 135 * able and willing to sign informed consent form exclusion criteria: * scheduled for surgery
benzydamine hydrochloride gargle in reducing propofol for ercp

Conditions: ERCP

Summary: it was a study aimed to determine the effectivity of benzydamine hydrochloride gargling in reducing propofol consumption in the endoscopic retrograde cholangiopancreatography (ercp) procedure.

the study was approved by ethics committee of indonesia university. it was a single-blind randomized clinical trial at cipto mangunkusumo hospital - jakarta during august to september 2018. 72 subjects were recruited and randomly assigned into 2 groups. patients in group b were given 0.15% mouthwash with benzydamine hydrochloride prior to procedure while patients in group c were given mouthwash with 15 ml of water. cumulative propofol consumption per minute per kg body weight, and incidence of postoperative sore throat were measured for each group.

Eligibility criteria:
inclusion criteria: * undergoing ercp * asa i-iii * bmi 18-30 kg/m2 exclusion criteria: * allergic to propofol * contraindicated to propofol * had throat wound or laceration * received analgesics or steroid in 24 hours priorly * unstable during sedation * procedure longer than 90 minutes

Keywords: propofol benzydamine hydrochloride sore throat endoscopic retrograde cholangiopancreatography
the role of hcg in thawed embryo transfer

Conditions: Infertility (IVF Patients)

Summary: this prospective randomized trial will assess the relevance, if any, of a corpus luteum induced by hcg in transfers of thawed embryos.

the current study is designed to carefully isolate the effect of a corpus luteum by ensuring that the presence or absence of a corpus luteum is the only difference between two study arms. this should be reliably achieved by administering an injection of hcg in one study arm, while the other study arm has identical treatment except for omitting the hcg.

Eligibility criteria:
inclusion criteria: 1. female adult expecting to receive transfer of a thawed embryo. 2. at least one available frozen blastocyst of transferrable quality. 3. non-menopausal female with at least one antral follicle. 4. use of pre-implantation genetic testing (pgt), embryos derived from donor oocytes and/or donor sperm, a gestational carrier, and history of prior transfer(s) regardless of outcome are allowed. 5. subsequent embryo transfers after failed transfers under this study are allowed, but not after a transfer that has resulted in ongoing pregnancy at ten weeks gestation under this study. exclusion criteria: 1. minors (age\<18 years). 2. use of embryo(s) frozen at another center. 3. patient insistent on transfer of two embryos. 4. patient or partner unable to provide informed consent in english. 5. patient already enrolled in any other research study for her embryo transfer. 6. history of anti-phospholipid syndrome or any other indication for use of lovenox in pregnancy. 7. patient for whom the physician assesses this protocol is inappropriate or unsafe.

Keywords: thawed embryo transfer
trial of septra for uncomplicated skin abscesses in patients at risk for community acquired methicillin-resistant staphylococcus aureus infection

Conditions: Abscess; Methicillin-Resistant Staphylococcus Aureus Infection

Summary: patients will be enrolled in a multi-center study (wilford hall medical center and brooke army medical center) to prospectively evaluate outcome after treatment for an uncomplicated skin abscess.

all patients will receive incision and drainage and wound cultures. patients will then be randomized to 1) septa double strength two pills orally twice a day x 7 days or 2)placebo. patients will then return to the emergency room on days 3 and 7 for wound repacking and evaluation. the primary outcome recurrence rates within 30 days of treatment. patients who are not improving at the following visit will then be treated with additional antibiotics if needed. data will be analyzed both by initial randomization and intention to treat.

Eligibility criteria:
inclusion criteria: * all patients age 18-65 who present to the emergency department with a skin abscess that requires incision and drainage. exclusion criteria: * patients with diabetes, hiv, cancer or other immunocompromised patients. * additionally, any patients who received antibiotics within one week of presentation or were hospitalized in previous month will be excluded to minimize potential confounding variables. * pregnant and breastfeeding patients will also be excluded due to possible safety concerns with antibiotic treatment. * patients with abscesses on head, face, perirectal, or periananal regions, abscesses with known tracks or fistulas to deeper structures, or abscesses requiring surgical drainage in an operating room are excluded. * finally, patients with sulfa allergy will be excluded.

Keywords: abscess cellulitis antibiotics mrsa
q-switched nd:yag in macular amyloidosis

Conditions: Macular Amyloidosis

Summary: the purpose of this study is to determine whether q-switched nd:yag laser therapy are effective in reduction of cutaneous macular amyloidosis.

we treat the macular amyloidosis cases by q-switched nd:yag laser and compare the before and after treatment situation by the photos and colorimetric assessment.

Eligibility criteria:
inclusion criteria: * macular amyloidosis confirmed cases exclusion criteria: * pregnancy and breast feeding * over 18 years old